Each year, 200 to 400 million people are infected in the underdeveloped and developing regions of the planet, causing the death of between 2 to 3 million of their inhabitans, most of which are children below 5 years of age. Several therapeutic agents that efficiently fight the disease already exist, but nevertheless; there is still a need to develop new antimalarial drugs to increase the therapeutic arsenal against the disease and to help prevent the different strains of already resistant Plasmodium parasites from acquiring further resistance to antimalarial drugs.
The researchers have also identified the gene where this compound inhibits the growth of the parasite, since it has a crucial role in its cycle inside the erythrocytes. The new compound is a non digestive protease inhibitor that does not allow the growth or development of the Plasmodium parasite inside the erythrocytes. This active compound, even considering its peptide origin, is expected to improve the activity and bioavailability of the drugs.
The identification of specific targets essential for the development of the parasite is an effective tool to facilitate the development of new drugs that cure infections by parasites resistant to current antimalarial drugs. The target identified, is a single gene with a very specific role for the parasite, and that is conserved and shared among all the species of plasmodium, which potentially implies a low probability for acquiring resistance. Also, the human host has several homologous genes to this target gene, but with different properties to the parasitic one, which is the possible reason for nearly non existent toxic effects of the new active compound in the mice used to test the drug, lending an additional advantage to this patented compound.
Área de Cultura Científica | alfa
Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan
Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
20.02.2017 | Materials Sciences
20.02.2017 | Health and Medicine
20.02.2017 | Health and Medicine